N/A N=20 Protection Against Insulin Resistance in Obesity
Obesity · Insulin Resistance
Primary: Insulin Sensitivity — 273; 817 nmol/kg FFM/min /(µU/mL Insulin)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Insulin Resistance in Adolescents
Insulin Resistance
Primary: Linear Relationship Between HOMA-IR and Cognitive Function (R-squared) — 0.205; 0.299; 0.738; 0.0264 R-squared — p=0.162
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
Phase 2 N=28 Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
Type 2 Diabetes · Insulin Resistance · Metabolic Syndrome
Primary: Change From Baseline in Insulin Sensitivity as Measured by Glucose Infusion Rate (GIR) — 17.95; 1.68 micromols/kg of FFM/minute — p=<0.001
Phase 2 N=35 Insulin Resistance and Testosterone in Women
Insulin Resistance · Postmenopause
Primary: Percent Change in Free Testosterone (T) — -6.9; -35.8; 12.1 percent change
Phase 2 N=6 Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
N/A N=21 Insulin and Polycystic Ovary Syndrome
PCOS
Primary: Renal Clearance of D-chiroinositol (DCI) at 12 Days — 4.75; 5.16 ml/min
Phase 2 N=35 Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Metabolic Syndrome · Insulin Resistance
Primary: Adipose Tissue Capillary Sprout Formation — 143.5; 122.1 number of capillary sprouts
N/A N=12 Insulin Resistance in Patients With Mood Disorder
Depression · Bipolar Disorder · Insulin Resistance
Primary: Hamilton Depression Rating Scale (HDRS-21) — 19.9; 13.0 units on a scale
Phase 2 N=24 Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome X
Primary: Triglycerides Levels at Week 12 — 210.6; 235.8 mg/dL — p=0.131
N/A N=66 Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Sub-optimal Vitamin D Status · Pre-diabetes · Insulin Resistance
Primary: Change in Insulin Resistance — 37.4; 36.3 μmol/kg/min (Step 2 GIR corrected)
N/A N=27 Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
Metabolic Syndrome X · Prediabetic State
Primary: Insulin Sensitivity — 1.48; 1.73; 1.89; 2.93 mg*kg^-1*min^-1
N/A N=11 Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance
Insulin Resistance
Primary: Insulin Sensitivity After 5-7 Days of Exercise — 3; 2.5 index score — p=<0.05
Phase 2 N=46 EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance
Hyperinsulinemia · Insulin Resistance · Obesity
Primary: Fasting Insulin — 8.1; 8.0; 6.3 uIU/mL — p=0.181
Phase 4 N=54 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Type 2 Diabetes · Diabetes
Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l
Phase 1 N=33 Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min
Phase 2 N=17 Effect of Salicylate on Glucose Metabolism in Insulin Resistance States
Insulin Resistance
Primary: Glucose — 7.1; 6.4 mmol/L
N/A N=25 Mechanisms of Insulin Resistance in Humans
Inflammation · Insulin Resistance
Primary: Insulin Signaling With Lipid Infusion — 0.4334; 0.7276; 0.5264; 0.3534 ratio
Phase 2 N=20 Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
Type 2 Diabetes Mellitus · Insulin Resistance
Primary: Peripheral Insulin Sensitivity (RD) Measured by the Change in Glucose Rates of Disappearance With Resveratrol or Placebo at Baseline and at 4 Weeks. — 6.573; 7.272…
N/A N=30 Effect of Endoplasmic Reticulum Stress on Metabolic Function
Insulin Resistance · Diabetes · Obesity
Primary: Body Composition — 39; 39; 37; 39 percentage
Phase 4 N=75 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Hyperlipidemia · Insulin Resistance · Type 2 Diabetes
Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01
N/A N=58 Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
Insulin Resistance · Obesity
Primary: Change in Muscle Strength — 0.37; -0.2 Ratio
N/A N=17 Insulin Secretion in Diabetes Before and After Glycemic Control
Diabetes · Hyperglycemia
Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min
N/A N=41 Fatty Acid Oxidation Defects and Insulin Sensitivity
Very Long-chain Acyl-CoA Dehydrogenase Deficiency · Trifunctional Protein Deficiency · Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Primary: Glucose Disposal Rate (Rd)- the Rate of Glucose Infusion to Maintain Euglycemia During Steady State Insulin Infusion in mg/Min — 709; 429; 842; 497 mg/min — p=0.136
Phase 4 N=68 Niacin, N-3 Fatty Acids and Insulin Resistance
Metabolic Syndrome · Hypertriglyceridemia
Primary: Serum TG — 233; 157; 176; 156 mg/dl
N/A N=32 Insulin Sensitivity in Patients With Atopic Dermatitis
Atopic Dermatitis/Eczema · Type 2 Diabetes
Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute
N/A N=4 Metabolomic Analysis of Hepatic Insulin Resistance
Type 2 Diabetes · Obesity
Primary: Insulin Sensitivity — 8 m value — p=<0.05
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1